A114450 Stock Overview
Engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Green Lifescience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,785.00 |
| 52 Week High | ₩4,545.00 |
| 52 Week Low | ₩1,452.00 |
| Beta | 1.15 |
| 1 Month Change | 8.25% |
| 3 Month Change | -22.22% |
| 1 Year Change | -20.67% |
| 3 Year Change | -75.16% |
| 5 Year Change | -67.53% |
| Change since IPO | -63.16% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 27% Share Price Plunge
Dec 09
Is Green Lifescience (KOSDAQ:114450) Using Debt In A Risky Way?
Nov 13Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 36% Dip In Price Shows Sentiment Is Matching Revenues
Sep 13The Market Doesn't Like What It Sees From Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Revenues Yet
Jul 30Recent updates
Why Investors Shouldn't Be Surprised By Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 27% Share Price Plunge
Dec 09Is Green Lifescience (KOSDAQ:114450) Using Debt In A Risky Way?
Nov 13Green Lifescience Co., Ltd.'s (KOSDAQ:114450) 36% Dip In Price Shows Sentiment Is Matching Revenues
Sep 13The Market Doesn't Like What It Sees From Green Lifescience Co., Ltd.'s (KOSDAQ:114450) Revenues Yet
Jul 30Health Check: How Prudently Does Green Lifescience (KOSDAQ:114450) Use Debt?
Mar 26KPX Lifescience.Co.Ltd (KOSDAQ:114450) Has Debt But No Earnings; Should You Worry?
Feb 22Investors Who Bought KPX Lifescience.Co.Ltd (KOSDAQ:114450) Shares Three Years Ago Are Now Up 180%
Dec 31
Shareholder Returns
| A114450 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 11.3% | 0.4% | 4.1% |
| 1Y | -20.7% | 30.0% | -6.3% |
Return vs Industry: A114450 underperformed the KR Life Sciences industry which returned 28% over the past year.
Return vs Market: A114450 underperformed the KR Market which returned -8.3% over the past year.
Price Volatility
| A114450 volatility | |
|---|---|
| A114450 Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 9.3% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A114450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A114450's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Jun-Yeong Yang | www.kpxls.com |
Green Lifescience Co., Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals and pesticides; and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, a piperacillin antibiotic intermediate; N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw drug, and AM19, an antibiotic intermediate, as well as 1,1'-carbonyldiimidazole, which are coupling reagents used in pharmaceuticals.
Green Lifescience Co., Ltd. Fundamentals Summary
| A114450 fundamental statistics | |
|---|---|
| Market cap | ₩35.70b |
| Earnings (TTM) | -₩12.66b |
| Revenue (TTM) | ₩21.59b |
1.7x
P/S Ratio-2.8x
P/E RatioIs A114450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A114450 income statement (TTM) | |
|---|---|
| Revenue | ₩21.59b |
| Cost of Revenue | ₩20.12b |
| Gross Profit | ₩1.47b |
| Other Expenses | ₩14.14b |
| Earnings | -₩12.66b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -633.19 |
| Gross Margin | 6.82% |
| Net Profit Margin | -58.66% |
| Debt/Equity Ratio | 13.5% |
How did A114450 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 03:31 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Green Lifescience Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|